Factores de riesgo para aterosclerosis en enfermedades autoinmunitarias sistémicas
Palabras clave:
ENFERMEDADES AUTOINMUNES, LUPUS ERITEMATOSO SISTÉMICO, ARTRITIS REUMATOIDE, ATEROSCLEROSIS, FACTORES DE RIESGOResumen
Los pacientes con enfermedades autoinmunitarias sistémicas (EAIS) presentan un riesgo incrementado de desarrollar aterosclerosis (AE). Esto responde a la presencia de factores de riesgo cardiovascular (FRCV) tradicionales –dislipemia, hipertensión arterial, diabetes, tabaquismo, obesidad, sedentarismo– y no tradicionales –actividad de la enfermedad, hiperhomocisteinemia, corticoterapia– que por diferentes caminos están incrementados. Los scores de riesgo cardiovascular absoluto no se mostraron útiles para predecir enfermedad cardiovascular en esta población, ya que al considerar solo los FRCV tradicionales subestiman el riesgo de futuros eventos. Las manifestaciones clínicas tienen características diferenciales que deben ser consideradas para no desestimarlas en la práctica clínica. El screening sistemático de los FRCV y la búsqueda de aterosclerosis subclínica deben estar dentro de la rutina de seguimiento de esta población. En ausencia de guías específicas y bajo el postulado que las EAIS imprimen un riesgo cardiovascular (CV) similar a la diabetes mellitus, los objetivos terapéuticos se asimilan a los propuestos para esta enfermedad. El control agresivo de los FRCV con medidas farmacológicas y no farmacológicas es el único camino capaz de reducir una de las principales causas de muerte en portadores de EAIS.
Citas
(1) Sari I, Okan T, Akar S, Cece H, Altay C, Secil M, et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006; 45(3): 283-6.
(2) Keser G, Aksu K, Tamsel S, Ozmen M, Kitapcioglu G, Kabaroglu C, et al. Increased thickness of the carotid artery intima-media assessed by ultrasonography in Behçet’s disease. Clin Exp Rheumatol 2005; 23(4 Suppl 38): S71-6.
(3) Seyahi E, Ugurlu S, Cumali R, Balci H, Seyahi N, Yurdakul S, et al. Atherosclerosis in Takayasu arteritis. Ann Rheum Dis 2006; 65(9): 1202-7
(4) Vaudo G, Bocci EB, Shoenfeld Y, Schillaci G, Wu R, Del Papa N, et al. Precocious intima-media thickening in patients with primary Sjögren’s syndrome. Arthritis Rheum 2005; 52(12): 3890-7.
(5) Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007; 36(4):203-9.
(6) Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992; 71(5): 291-302.
(7) Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Janse-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145(5): 408-15.
(8) 8. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44(10): 2331-7.
(9) 9. Korkmaz C, Cansu DU, Kasifoglu T. Myocardial infarction in young patients (< or =35 years of age) with systemic lupus erythematosus: a case report and clinical analysis of the literature. Lupus 2007; 16(4): 289-97.
(10) Bruce IN, Urowitz MB, Gladman DD, Hallett DC. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999; 26(10): 2137-43.
(11) Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004; 93(2): 198-200.
(12) Freire BF, da Silva RC, Fabro AT, dos Santos DC. Is systemic lupus erithematosus a new risk factor for atherosclerosis? Arq Bras Cardiol 2006; 87(3): 300-6.
(13) Kumeda Y, Inaba M, Goto H, Nagata M, Henmi Y, Furumitsu Y, et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46(6): 1489-97.
(14) Park YB, Ahn CW, Choi HK, Lee SH, In BH, Lee HC, et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002; 46(7): 1714-9.
(15) Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349(25): 2399-406.
(16) Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62(11): 1071-7.
(17) González-Juanatey C, Llorca J, Testa A, Revuelta J, García-Porrua C, González-Gay MA. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003; 82(6): 407-13.
(18) Ahmad Y, Bodill H, Shelmerdine J. Antiphospholipid antibodies (APLA) contribute to atherogenesis in SLE. Arthritis Rheum 2004; 50(Suppl 1): S191.
(19) Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Pratt JE, Tracy RP, Kuller LH, et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004; 50(1): 151-9.
(20) Cuomo G, Di Micco P, Niglio A, La Montagna G, Valentini G. Atherosclerosis and rheumatoid arthritis: relationships between intima-media thickness of the common carotid arteries and disease activity and disability. Reumatismo 2004; 56(4): 242-6.
(21) Il’ina AE, Kliukvina NG, Aleksandrova EN, Popkova TV, Novikov AA, Mach ES, et al. Atherosclerotic lesion of the vessels in systemic lupus erythematosus in males: relations with concentration of C-reactive protein. Ter Arkh 2005; 77(6): 61-5.
(22) Souza AW, Hatta FS, Miranda F, Sato EI. Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: frequency and associated risk factors. Sao Paulo Med J 2005; 123(3): 137-42.
(23) Jiménez S, García-Criado MA, Tàssies D, Reverter JC, Cervera R, Gilabert MR, et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 2005; 44(6): 756-61.
(24) Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, et al. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005; 46(1): 194-9.
(25) del Rincón I, Freeman GL, Haas RW, O’Leary DH, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005; 52(11): 3413-23.
(26) Maksimowicz-McKinnon K, Magder LS, Petri M. Predictors of carotid atherosclerosis in systemic lupus erythematosus. J Rheumatol 2006; 33(12): 2458-63.
(27) Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006; 144(4): 249-56.
(28) Bhatt SP, Handa R, Gulati GS, Sharma S, Pandey RM, Aggarwal P, et al. Atherosclerosis in Asian Indians with systemic lupus erythematosus. Scand J Rheumatol 2006; 35(2): 128-32.
(29) Grover S, Sinha RP, Singh U, Tewari S, Aggarwal A, Misra R. Subclinical atherosclerosis in rheumatoid arthritis in India. J Rheumatol 2006; 33(2): 244-7.
(30) Ahmad Y, Shelmerdine J, Bodill H, Lunt M, Pattrick MG, Teh LS, et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford) 2007; 46(6): 983-8.
(31) Popkova TV, Khelkovskaia AN, Mach ES, Aleksandrova EN, Novikov AA, Novikova DS, et al. Cardiovascular diseases in rheumatoid arthritis. Ter Arkh 2007; 79(5): 9-14.
(32) Carotti M, Salaffi F, Mangiacotti M, Cerioni A, Giuseppetti GM, Grassi W. Atherosclerosis in rheumatoid arthritis: the role of high-resolution B mode ultrasound in the measurement of the arterial intima-media thickness. Reumatismo 2007; 59(1): 38-49.
(33) Dessein PH, Norton GR, Woodiwiss AJ, Joffe BI, Wolfe F. Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2007; 34(5): 943-51.
(34) Bruce IN, Burns RJ, Gladman DD, Urowitz MB. Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities. J Rheumatol 2000; 27(10): 2372-7.
(35) Sella EM, Sato EI, Leite WA, Oliveira Filho JA, Barbieri A. Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus. Ann Rheum Dis 2003; 62811): 1066-70.
(36) Espinola Zavaleta N, Alexánderson E, Soto ME, Flores M, Amigo MC. Analysis of the ulsefulnes of contrast echocardiography and nuclear medicine in cardiovascular affection due to autoimmune diseases. Arch Cardiol Mex 2005; 75(1): 42-8.
(37) Manger K, Kusus M, Forster C, Ropers D, Daniel WG, Kalden JR, et al. Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 2003; 62(9): 846-50.
(38) Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349(25): 2407-15.
(39) Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005; 52(10): 3045-53.
(40) Chung CP, Oeser A, Avalos I, Raggi P, Stein CM. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 2006; 15(9): 562-9.
(41) Theodoridou A, Bento L, D’Cruz DP, Khamashta MA, Hughes GR. Prevalence and associations of an abnormal ankle-brachial index in systemic lupus erythematosus: a pilot study. Ann Rheum Dis 2003; 62(12): 1199-203.
(42) Alkaabi JK, Ho M, Levison R, Pullar T, Belch JJ. Rheumatoid arthritis and macrovascular disease. Rheumatology (Oxford) 2003; 42(2): 292-7.
(43) Tso TK, Huang WN, Huang HY, Chang CK. Association of brachial-ankle pulse wave velocity with cardiovascular risk factors in systemic lupus erythematosus. Lupus 2005; 14(11): 878-83.
(44) El-Magadmi M, Bodill H, Ahmad Y, Durrington PN, Mackness M, Walker M, et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004; 110(4): 399-404.
(45) Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004; 63(1): 31-5.
(46) Tani C, Mosca M, d’Ascanio A, Versari D, Virdis A, Ghiadoni L, et al. Chronic inflammation and endothelial dysfunction: analysis of a cohort of patients with SLE and UCTD. Reumatismo 2006; 58(3): 212-8.
(47) Wright SA, O’Prey FM, Rea DJ, Plumb RD, Gamble AJ, Leahey WJ, et al. Microcirculatory hemodynamics and endothelial dysfunction in systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2006; 26(10): 2281-7.
(48) Kiss E, Soltesz P, Der H, Kocsis Z, Tarr T, Bhattoa H, et al. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun 2006; 27(4): 211-7.
(49) Piper MK, Raza K, Nuttall SL, Stevens R, Toescu V, Heaton S, et al. Impaired endothelial function in systemic lupus erythematosus. Lupus 2007; 16(2): 84-8.
(50) Hirata K, Kadirvelu A, Kinjo M, Sciacca R, Sugioka K, Otsuka R, et al. Altered coronary vasomotor function in young patients with systemic lupus erythematosus. Arthritis Rheum 2007; 56(6): 1904-9.
(51) Brodszki J, Bengtsson C, Länne T, Nived O, Sturfelt G, Marsál K. Abnormal mechanical properties of larger arteries in postmenopausal women with systemic lupus erythematosus. Lupus 2004; 13(12): 917-23.
(52) Abu-Shakra M, Polychuck I, Szendro G, Bolotin A, Jonathan BS, Flusser D, et al. Duplex study of the carotid and femoral arteries of patients with rheumatoid arthritis: a controlled study. Semin Arthritis Rheum 2005; 35(1): 18-23.
(53) Bruce I. ‘Not only... but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44(12): 1492-1502.
(54) van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007; 66(2): 184-8.
(55) Borba EF, Bonfá E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997; 6(6): 533-9.
(56) Borba EF, Santos RD, Bonfá E, Vinagre CG, Pileggi FJ, Cossermelli W, et al. Lipoprotein (a) levels in systemic lupus erythematosus J Rheumatol 1994; 21(2): 220-3.
(57) Tisseverasinghe A, Lim S, Greenwood C, Urowitz M, Gladman D, Fortin PR. Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. Arthritis Rheum 2006; 54(7): 2211-9.
(58) Isik A, Koca SS, Ustundag B, Celik H, Yildirim A. Paraoxonase and arylesterase levels in rheumatoid arthritis. Clin Rheumatol 2007; 26(3): 342-8.
(59) McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54(8): 2541-9.
(60) López LR, Salazar-Paramo M, Palafox-Sánchez C, Hurley BL, Matsuura E, García-De La Torre. Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus 2006; 15(2): 80-6.
(61) Lourida ES, Georgiadis AN, Papavasiliou EC, Papatha-nasiou AI, Drosos AA, Tselepis AD. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2. Arthritis Res Ther 2007; 9(1): R19.
(62) Wada Y, Kuroda T, Murasawa A, Tanabe N, Nakano M, Gejyo F. Autoantibodies against oxidized low-density lipoprotein (LDL) and carotid atherosclerosis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23(4): 482-6.
(63) Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002; 46(11): 2957-63.
(64) de Carvalho JF, Borba EF, Viana VS, Bueno C, Leon EP, Bonfá E. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? Arthritis Rheum 2004; 50(11): 3610-5.
(65) Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 1994; 21(7): 1264-7.
(66) Prokopowitsch AS, Diógenes AHM, Borges CT, Torigoe DY, Kochen J, Laurindo IMM. Leflunomide induces progressive increase in rheumatoid arthritis lipid profile. Arthritis Rheum 2002; 46: S164.
(67) Nuttall SL, Heaton S, Piper MK, Martin U, Gordon C. Cardiovascular risk in systemic lupus erythematosus–evidence of increased oxidative stress and dyslipidaemia. Rheumatology (Oxford) 2003; 42(6): 758-62.
(68) Schoenfeld Y, Krause I, Krause I, Khamashta M, Hughes G. The Sixth International Lupus Conference, Barcelona 24-28 March 2001. Lupus 2001; 10(8): 580-7.
(69) Bruce IN, Urowitz MB, Gladman DD, Ibañez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003; 48(11): 3159-67.
(70) Telles R Weiss, Lanna C Costa Duarte, Ferreira GA, de Carvalho MA Parreiras, Ribeiro AL. Freqüência de doença cardiovascular aterosclerótica e de seus fatores de risco em pacientes com lúpus eritematoso sistêmico. Rev Bras Reumatol 2007; 47(3): 165-73.
(71) Pieretti J, Roman MJ, Devereux RB, Lockshin MD, Crow MK, Paget SA, et al. Systemic lupus erythematosus predicts increased left ventricular mass. Circulation 2007; 116(4): 419-26.
(72) Chaiamnuay S, Bertoli AM, Roseman JM, McGwin G, Apte M, Durán S, et al. African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV). Ann Rheum Dis 2007; 66(5): 618-22.
(73) Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48(6): 1530-42.
(74) Cisternas M, Gutiérrez MA, Klaassen J, Acosta AM, Jacobelli S. Cardiovascular risk factors in Chilean patients with rheumatoid arthritis. J Rheumatol 2002; 29(8): 1619-22.
(75) Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of non-steroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153(4): 477-84.
(76) El-Magadmi M, Ahmad Y, Turkie W, Yates AP, Sheikh N, Berstein RM, et al. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 2006; 33(1): 50-6.
(77) Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007; 66(2): 208-14.
(78) Escárcega RO, García-Carrasco M, Fuentes-Alexandro S, Jara LJ, Rojas-Rodriguez J, Escobar-Linares, LE, et al. Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. Autoimmun Rev 2006; 6(1): 48-53.
(79) Rosenstein ED, Advani S, Reitz RE, Kramer N. The prevalence of insulin receptor antibodies in patients with systemic lupus erythematosus and related conditions. J Clin Rheumatol 2001; 7(6): 371-3.
(80) del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44(12): 2737-45.
(81) Dessein PH, Tobias M, Veller MG. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2006; 33(12): 2425-32.
(82) La Montagna G, Cacciapuoti F, Buono R, Manzella D, Mennillo GA, Arciello A, et al. Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diab Vasc Dis Res 2007; 4(2): 130-5.
(83) Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006; 54(9): 2765-75.
(84) Dessein PH, Joffe BI, Stanwix AE, Christian BF, Veller M. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol 2004; 31(5): 867-74.
(85) Paolisso G, Valentini G, Giugliano D, Marrazzo G, Tirri R, Gallo M, et al. Evidence for peripheral impaired glucose handling in patients with connective tissue disease. Metabolism 1991; 40(9): 902-7.
(86) Oeser A, Chung CP, Asanuma Y, Avalos I, Stein CM. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 2005; 52(11): 3651-9.
(87) Inaba M, Tanaka K, Goto H, Sakai S, Yamada S, Naka H, et al. J Rheumatol 2007; 34(2): 290-5.
(88) Bartfai T, Waalen J, Buxbaum JN. Adipose tissue as a modulator of clinical inflammation: does obesity reduce the prevalence of rheumatoid arthritis? J Rheumatol 2007; 34(3): 488-92.
(89) Keyser RE, Rus V, Cade WT, Kalappa N, Flores RH, Handwerger BS. Evidence for aerobic insufficiency in women with systemic Lupus erythematosus. Arthritis Rheum 2003; 49(1): 16-22.
(90) Tench C, Bentley D, Vleck V, McCurdie I, White P, D’ Cruz D. Aerobic fitness, fatigue, and physical disability in systemic lupus erythematosus. J Rheumatol 2002; 29(3): 474-81.
(91) Toloza SM, Uribe AG, McGwin G Jr, Alarcón GS, Fessler BJ, Bastian HM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 50(12): 3947-57.
(92) Ho KT, Ahn CW, Alarcón GS, Baethge BA, Tan FK, Roseman J, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 2005; 44(10): 1303-7.
(93) Ghaussy NO, Sibbitt W Jr, Bankhurst AD, Qualls CR. Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol 2003; 30(6): 1215-21.
(94) Gerli R, Sherer Y, Vaudo G, Schillaci G, Gilburd B, Giordano A, et al. Early atherosclerosis in rheumatoid arthritis: effects of smoking on thickness of the carotid artery intima media. Ann N Y Acad Sci 2005; 1051: 281-90.
(95) Glossop JR, Dawes PT, Mattey DL. Association between cigarette smoking and release of tumour necrosis factor alpha and its soluble receptors by peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006; 45(10): 1223-9.
(96) Papadopoulos NG, Alamanos Y, Voulgari PV, Epagelis EK, Tsifetaki N, Drosos AA. Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheumatol 2005; 23(6): 861-6.
(97) Banerjee KK, Marimuthu P, Sarkar A, Chaudhuri RN. Influence of cigarette smoking on Vitamin C, glutathione and lipid peroxidation status. Indian J Public Health 1998; 42(1): 20-3.
(98) Von Feldt JM, Scalzi LV, Cucchiara AJ, Morthala S, Kealey C, Flagg SD, et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54(7): 2220-7.
(99) López-Olivo MA, González-López L, García-González A, Villa-Manzano AI, Cota-Sánchez AR, Salazar-Paramo M, et al. Factors associated with hyperhomocysteinaemia in Mexican patients with rheumatoid arthritis. Scand J Rheumatol 2006; 35(2): 112-6.
(100) Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352(16): 1685-95.
(101) Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
(102) González-Gay MA, González-Juanatey C, Piñeiro A, García-Porrua C, Testa A, Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005; 32(7): 1219-23.
(103) del Rincón I, Williams K, Stern MP, Freeman GL, O’Leary DH, Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003; 48(7): 1833-40.
(104) Tani C, Mosca M, d’Ascanio A, Versari D, Virdis A, Ghiadoni L, et al. Chronic inflammation and endothelial dysfunction: analysis of a cohort of patients with SLE and UCTD. Reumatismo 2006; 58(3): 212-8.
(105) Ferreira GA, Navarro TP, Telles RW, Carvalho MAP, Sato EI. A terapia immunosuppressive é associada com a melhor função endothelial em pacientes de SLE. Uma comunicação pessoal. São Paulo: Universidade Federal de São Paulo. Escola Paulista de Medicina. Divisão do Reumatologia, 2007.
(106) Popkova TV, Khelkovskaia AN, Mach ES, Aleksandrova EN, Novikov AA, Novikova DS, et al. Cardiovascular diseases in rheumatoid arthritis. Op. cit. ref. 31.
(107) Turesson C, McClelland RL, Christianson TJ, Matteson EL. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2007;
66(1): 70-5.
(108) van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006; 8(5): R151.
(109) MacGregor AJ, Dhillon VB, Binder A, Forte CA, Knight BC, Betteridge DJ, et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 1992; 51(2): 152-5.
(110) del Rincón I, O’Leary DH, Haas RW, Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004; 50(12): 3813-22.
(111) Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107(9): 1303-7
(112) Ahmad Y, Bodill H, Shelmerdine J. Antiphospholipid antibodies (APLA) contribute to atherogenesis in SLE. Op. cit. ref. 18.
(113) Svenungsson E, Jensen-Urstad K, Heimbürger M, Silveira A, Hamsten A, defaire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104(16): 1887-93.
(114) Sherer Y, Gerli R, Gilburd B, Bartoloni Bocci E, Vaudo G, Mannarino E, et al. Thickened carotid artery intima-media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies. Lupus 2007; 16(4): 259-64.
(115) Fischer K, Brzosko M, Walecka A, Ostanek L, Sawicki M. Antiendothelial cell antibodies as a risk factor of atherosclerosis in systemic lupus erythematosus. Ann Acad Med Stetin 2006; 52 (Suppl 2): 95-9.
(116) Asanuma Y, Chung CP, Oeser A, Shintani A, Stanley E, Raggi P, Stein CM. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006; 33(3): 539-45.
(117) Jackson M, Ahmad Y, Bruce IN, Coupes B, Brenchley PE. Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus. Arthritis Res Ther 2006; 8(3): R81.
(118) Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A, Raggi P, et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006; 8(6): R186.
(119) Sella EMC, Sato EI. Avaliaçao de fatores de rsco coronário e dor torácica em lúpus eritematoso sistêmico. Rev bras reumatol 2002; 42(3): 160-8.
(120) Banks M, Pace A, Kitas G. Acute coronary syndromes present atipically and recurr more frequently in rheumatoid arthritis than matched controls. Arthritis Rheum 2001; 44: S53.
(121) Maradit-Kremers H, Crownson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden death in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52(2): 402-11.
(122) Costenbader KH, Wright E, Liang MH, Karlson EW. Cardiac risk factor awareness and management in patients with systemic lupus erythematosus. Arthritis Rheum 2004; 51(6): 983-8.
(123) Haq I, Isenberg D. How does one assess and monitor patients with systemic lupus erythematosus in daily clinical practice? Best Pract Res Clin Rheumatol 2000; 16(2): 181-94.
(124) Nikpour M, Urowitz M, Gladman D. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2005; 31(2): 329-54.
(125) Wallace DJ. What’s New in the management of lupus since 2000? J Clin Rheumatol 2006; 12(6): 307-13.
(126) Rahman A, Bessant R, Isenberg DA. What do lupus specialists believe about managing conventional cardiovascular risk factors in patients with systemic lupus erythematosus? Lupus 2006; 15(10): 697-9.
(127) Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus–proposed guidelines for risk factor management. Rheumatology (Oxford) 2004; 43(1): 7-12.
(128) American Diabetes Association. Standards of medical care in diabetes–2006. Diabetes Care 2006; 29 (Suppl 1): S4-42.
(129) Mancini GB. Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease. Am J Med 1998; 105(1A): 40S-47S.
(130) Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002; 40(3): 505-10.
(131) Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease a meta-analysis of patient-level data. Ann Intern Med 2001; 135(2): 73-87.
(132) Ruggenenti P, Mise N, Pisoni R, Arnoldi F, Pezzotta A, Perna A, et al. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 2003; 107(4): 586-92.
(133) Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19(6): 540-56.
(134) Ferreira GA, Navarro TP, Telles R, Andrade LE, Sato EI. Atorvastatin therapy improves endothelial-dependent vasodilatation in patients with lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 2007; 46(10): 1560-5.
(135) Jury EC, Ehrenstein MR. Statins: immunomodulators for autoimmune rheumatic disease? Lupus 2005; 14(3): 192-6.
(136) Bruce IN. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol 2005; 19(5): 823-38.
(137) Sparrow CP, Burton C, Hernández M, Mundt S, Hassing H, patel S, et al. Simvastatin has antiinflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21(1): 115-21.
(138) Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors:statins as anti-inflammatory agents? Circulation 2004; 109(21 Suppl. 1): II18-26.
(139) Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in NZB/WF1 mice. J Immunol 2004; 173(12): 7641-6.
(140) Jury EC, Ehrenstein MR. Statins: immunomodulators for autoimmune rheumatic disease? Lupus 2005; 14(3): 192-6.
(141) Mäki-Petäjä KM, Booth AD, Hall FC, Wallace SM, Brown J, McEniery CM, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007; 50(9): 852-8.
(142) Van Doornum S, McColl G, Wicks IP. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63(12): 1571-5.
(143) McCarey DW, McInnes LB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebocontrolled trial. Lancet 2004; 363(9426): 2015-21.
(144) Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995; 332(15): 993-7.
(145) Sloop GD. Decreased prevalence of symptomatic atherosclerosis in arthritis patients on long-term aspirin therapy. Angiology 1998; 49(10): 827-32.
(146) Borba EF, Bonfá E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 2001; 28(4): 780-5.
(147) Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000; 27(9): 2142-5.
(148) Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89(3): 322-6.
(149) Sachet JC, Borbá EF, Bonfá E, Vinagre CG, Silva VM, Maranhão RC. Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 2007; 16(4): 273-8.
(150) Johansson E, Forsberg K, Johnsson H. Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasis 1981; 10(2): 89-96.
(151) Prowse C, Pepper D, Dawes J. Prevention of the platelet alphagranule release reaction by membrane-active drugs. Thromb Res 1982; 25(3): 219-27.
(152) Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298(2): 187-93.
(153) Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S. Vascular stiffness with systemic lupus erythematosus. Hypertension 2001; 37(4): 1075-82.
(154) van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Op. cit. ref. 108.
(155) Wållberg-Jonsson S, Ohman M, Rantapää-Dahlqvist S. Which factors are related to the presence of atherosclerosis in rheumatoid arthritis? Scand J Rheumatol 2004; 33(6): 373-9.
(156) Pham T, Gossec L, Constantin A, Pavy S, Bruckert E, Cantagrel A, et al. Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006; 73(4): 379-87.
(157) Choi HK, Seeger JD. Lipid profiles among US elderly with untreated rheumatoid arthritis–the Third National Health and Nutrition Examination Survey. J Rheumatol 2005; 32(12): 2311-6.
(158) Dessein PH, Joffe BI, Stanwix AE. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res 2002; 4(6): R12.
(159) Cardillo C, Schinzari F, Mores N, Mettimano M, Melina D, Zoli A, et al. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis. Clin Pharmacol Ther 2006; 80(3): 275-81.
(160) González-Juanatey C, Llorca J, García-Porrua C, Martin J, González-Gay MA. Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 2006; 55(1): 150-3.
(161) Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006; 33(12): 2440-6.
(162) González-Gay MA, De Matias JM, González-Juanatey C, García-Porrua C, Sánchez-Andrade A, Martin J, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24(1): 83-6.
(2) Keser G, Aksu K, Tamsel S, Ozmen M, Kitapcioglu G, Kabaroglu C, et al. Increased thickness of the carotid artery intima-media assessed by ultrasonography in Behçet’s disease. Clin Exp Rheumatol 2005; 23(4 Suppl 38): S71-6.
(3) Seyahi E, Ugurlu S, Cumali R, Balci H, Seyahi N, Yurdakul S, et al. Atherosclerosis in Takayasu arteritis. Ann Rheum Dis 2006; 65(9): 1202-7
(4) Vaudo G, Bocci EB, Shoenfeld Y, Schillaci G, Wu R, Del Papa N, et al. Precocious intima-media thickening in patients with primary Sjögren’s syndrome. Arthritis Rheum 2005; 52(12): 3890-7.
(5) Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007; 36(4):203-9.
(6) Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992; 71(5): 291-302.
(7) Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Janse-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145(5): 408-15.
(8) 8. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44(10): 2331-7.
(9) 9. Korkmaz C, Cansu DU, Kasifoglu T. Myocardial infarction in young patients (< or =35 years of age) with systemic lupus erythematosus: a case report and clinical analysis of the literature. Lupus 2007; 16(4): 289-97.
(10) Bruce IN, Urowitz MB, Gladman DD, Hallett DC. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999; 26(10): 2137-43.
(11) Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004; 93(2): 198-200.
(12) Freire BF, da Silva RC, Fabro AT, dos Santos DC. Is systemic lupus erithematosus a new risk factor for atherosclerosis? Arq Bras Cardiol 2006; 87(3): 300-6.
(13) Kumeda Y, Inaba M, Goto H, Nagata M, Henmi Y, Furumitsu Y, et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46(6): 1489-97.
(14) Park YB, Ahn CW, Choi HK, Lee SH, In BH, Lee HC, et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002; 46(7): 1714-9.
(15) Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349(25): 2399-406.
(16) Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62(11): 1071-7.
(17) González-Juanatey C, Llorca J, Testa A, Revuelta J, García-Porrua C, González-Gay MA. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003; 82(6): 407-13.
(18) Ahmad Y, Bodill H, Shelmerdine J. Antiphospholipid antibodies (APLA) contribute to atherogenesis in SLE. Arthritis Rheum 2004; 50(Suppl 1): S191.
(19) Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Pratt JE, Tracy RP, Kuller LH, et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004; 50(1): 151-9.
(20) Cuomo G, Di Micco P, Niglio A, La Montagna G, Valentini G. Atherosclerosis and rheumatoid arthritis: relationships between intima-media thickness of the common carotid arteries and disease activity and disability. Reumatismo 2004; 56(4): 242-6.
(21) Il’ina AE, Kliukvina NG, Aleksandrova EN, Popkova TV, Novikov AA, Mach ES, et al. Atherosclerotic lesion of the vessels in systemic lupus erythematosus in males: relations with concentration of C-reactive protein. Ter Arkh 2005; 77(6): 61-5.
(22) Souza AW, Hatta FS, Miranda F, Sato EI. Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: frequency and associated risk factors. Sao Paulo Med J 2005; 123(3): 137-42.
(23) Jiménez S, García-Criado MA, Tàssies D, Reverter JC, Cervera R, Gilabert MR, et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 2005; 44(6): 756-61.
(24) Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, et al. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005; 46(1): 194-9.
(25) del Rincón I, Freeman GL, Haas RW, O’Leary DH, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005; 52(11): 3413-23.
(26) Maksimowicz-McKinnon K, Magder LS, Petri M. Predictors of carotid atherosclerosis in systemic lupus erythematosus. J Rheumatol 2006; 33(12): 2458-63.
(27) Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006; 144(4): 249-56.
(28) Bhatt SP, Handa R, Gulati GS, Sharma S, Pandey RM, Aggarwal P, et al. Atherosclerosis in Asian Indians with systemic lupus erythematosus. Scand J Rheumatol 2006; 35(2): 128-32.
(29) Grover S, Sinha RP, Singh U, Tewari S, Aggarwal A, Misra R. Subclinical atherosclerosis in rheumatoid arthritis in India. J Rheumatol 2006; 33(2): 244-7.
(30) Ahmad Y, Shelmerdine J, Bodill H, Lunt M, Pattrick MG, Teh LS, et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford) 2007; 46(6): 983-8.
(31) Popkova TV, Khelkovskaia AN, Mach ES, Aleksandrova EN, Novikov AA, Novikova DS, et al. Cardiovascular diseases in rheumatoid arthritis. Ter Arkh 2007; 79(5): 9-14.
(32) Carotti M, Salaffi F, Mangiacotti M, Cerioni A, Giuseppetti GM, Grassi W. Atherosclerosis in rheumatoid arthritis: the role of high-resolution B mode ultrasound in the measurement of the arterial intima-media thickness. Reumatismo 2007; 59(1): 38-49.
(33) Dessein PH, Norton GR, Woodiwiss AJ, Joffe BI, Wolfe F. Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2007; 34(5): 943-51.
(34) Bruce IN, Burns RJ, Gladman DD, Urowitz MB. Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities. J Rheumatol 2000; 27(10): 2372-7.
(35) Sella EM, Sato EI, Leite WA, Oliveira Filho JA, Barbieri A. Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus. Ann Rheum Dis 2003; 62811): 1066-70.
(36) Espinola Zavaleta N, Alexánderson E, Soto ME, Flores M, Amigo MC. Analysis of the ulsefulnes of contrast echocardiography and nuclear medicine in cardiovascular affection due to autoimmune diseases. Arch Cardiol Mex 2005; 75(1): 42-8.
(37) Manger K, Kusus M, Forster C, Ropers D, Daniel WG, Kalden JR, et al. Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 2003; 62(9): 846-50.
(38) Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349(25): 2407-15.
(39) Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005; 52(10): 3045-53.
(40) Chung CP, Oeser A, Avalos I, Raggi P, Stein CM. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 2006; 15(9): 562-9.
(41) Theodoridou A, Bento L, D’Cruz DP, Khamashta MA, Hughes GR. Prevalence and associations of an abnormal ankle-brachial index in systemic lupus erythematosus: a pilot study. Ann Rheum Dis 2003; 62(12): 1199-203.
(42) Alkaabi JK, Ho M, Levison R, Pullar T, Belch JJ. Rheumatoid arthritis and macrovascular disease. Rheumatology (Oxford) 2003; 42(2): 292-7.
(43) Tso TK, Huang WN, Huang HY, Chang CK. Association of brachial-ankle pulse wave velocity with cardiovascular risk factors in systemic lupus erythematosus. Lupus 2005; 14(11): 878-83.
(44) El-Magadmi M, Bodill H, Ahmad Y, Durrington PN, Mackness M, Walker M, et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004; 110(4): 399-404.
(45) Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004; 63(1): 31-5.
(46) Tani C, Mosca M, d’Ascanio A, Versari D, Virdis A, Ghiadoni L, et al. Chronic inflammation and endothelial dysfunction: analysis of a cohort of patients with SLE and UCTD. Reumatismo 2006; 58(3): 212-8.
(47) Wright SA, O’Prey FM, Rea DJ, Plumb RD, Gamble AJ, Leahey WJ, et al. Microcirculatory hemodynamics and endothelial dysfunction in systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2006; 26(10): 2281-7.
(48) Kiss E, Soltesz P, Der H, Kocsis Z, Tarr T, Bhattoa H, et al. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun 2006; 27(4): 211-7.
(49) Piper MK, Raza K, Nuttall SL, Stevens R, Toescu V, Heaton S, et al. Impaired endothelial function in systemic lupus erythematosus. Lupus 2007; 16(2): 84-8.
(50) Hirata K, Kadirvelu A, Kinjo M, Sciacca R, Sugioka K, Otsuka R, et al. Altered coronary vasomotor function in young patients with systemic lupus erythematosus. Arthritis Rheum 2007; 56(6): 1904-9.
(51) Brodszki J, Bengtsson C, Länne T, Nived O, Sturfelt G, Marsál K. Abnormal mechanical properties of larger arteries in postmenopausal women with systemic lupus erythematosus. Lupus 2004; 13(12): 917-23.
(52) Abu-Shakra M, Polychuck I, Szendro G, Bolotin A, Jonathan BS, Flusser D, et al. Duplex study of the carotid and femoral arteries of patients with rheumatoid arthritis: a controlled study. Semin Arthritis Rheum 2005; 35(1): 18-23.
(53) Bruce I. ‘Not only... but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44(12): 1492-1502.
(54) van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007; 66(2): 184-8.
(55) Borba EF, Bonfá E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997; 6(6): 533-9.
(56) Borba EF, Santos RD, Bonfá E, Vinagre CG, Pileggi FJ, Cossermelli W, et al. Lipoprotein (a) levels in systemic lupus erythematosus J Rheumatol 1994; 21(2): 220-3.
(57) Tisseverasinghe A, Lim S, Greenwood C, Urowitz M, Gladman D, Fortin PR. Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. Arthritis Rheum 2006; 54(7): 2211-9.
(58) Isik A, Koca SS, Ustundag B, Celik H, Yildirim A. Paraoxonase and arylesterase levels in rheumatoid arthritis. Clin Rheumatol 2007; 26(3): 342-8.
(59) McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54(8): 2541-9.
(60) López LR, Salazar-Paramo M, Palafox-Sánchez C, Hurley BL, Matsuura E, García-De La Torre. Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus 2006; 15(2): 80-6.
(61) Lourida ES, Georgiadis AN, Papavasiliou EC, Papatha-nasiou AI, Drosos AA, Tselepis AD. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2. Arthritis Res Ther 2007; 9(1): R19.
(62) Wada Y, Kuroda T, Murasawa A, Tanabe N, Nakano M, Gejyo F. Autoantibodies against oxidized low-density lipoprotein (LDL) and carotid atherosclerosis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23(4): 482-6.
(63) Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002; 46(11): 2957-63.
(64) de Carvalho JF, Borba EF, Viana VS, Bueno C, Leon EP, Bonfá E. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? Arthritis Rheum 2004; 50(11): 3610-5.
(65) Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 1994; 21(7): 1264-7.
(66) Prokopowitsch AS, Diógenes AHM, Borges CT, Torigoe DY, Kochen J, Laurindo IMM. Leflunomide induces progressive increase in rheumatoid arthritis lipid profile. Arthritis Rheum 2002; 46: S164.
(67) Nuttall SL, Heaton S, Piper MK, Martin U, Gordon C. Cardiovascular risk in systemic lupus erythematosus–evidence of increased oxidative stress and dyslipidaemia. Rheumatology (Oxford) 2003; 42(6): 758-62.
(68) Schoenfeld Y, Krause I, Krause I, Khamashta M, Hughes G. The Sixth International Lupus Conference, Barcelona 24-28 March 2001. Lupus 2001; 10(8): 580-7.
(69) Bruce IN, Urowitz MB, Gladman DD, Ibañez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003; 48(11): 3159-67.
(70) Telles R Weiss, Lanna C Costa Duarte, Ferreira GA, de Carvalho MA Parreiras, Ribeiro AL. Freqüência de doença cardiovascular aterosclerótica e de seus fatores de risco em pacientes com lúpus eritematoso sistêmico. Rev Bras Reumatol 2007; 47(3): 165-73.
(71) Pieretti J, Roman MJ, Devereux RB, Lockshin MD, Crow MK, Paget SA, et al. Systemic lupus erythematosus predicts increased left ventricular mass. Circulation 2007; 116(4): 419-26.
(72) Chaiamnuay S, Bertoli AM, Roseman JM, McGwin G, Apte M, Durán S, et al. African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV). Ann Rheum Dis 2007; 66(5): 618-22.
(73) Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48(6): 1530-42.
(74) Cisternas M, Gutiérrez MA, Klaassen J, Acosta AM, Jacobelli S. Cardiovascular risk factors in Chilean patients with rheumatoid arthritis. J Rheumatol 2002; 29(8): 1619-22.
(75) Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of non-steroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153(4): 477-84.
(76) El-Magadmi M, Ahmad Y, Turkie W, Yates AP, Sheikh N, Berstein RM, et al. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 2006; 33(1): 50-6.
(77) Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007; 66(2): 208-14.
(78) Escárcega RO, García-Carrasco M, Fuentes-Alexandro S, Jara LJ, Rojas-Rodriguez J, Escobar-Linares, LE, et al. Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. Autoimmun Rev 2006; 6(1): 48-53.
(79) Rosenstein ED, Advani S, Reitz RE, Kramer N. The prevalence of insulin receptor antibodies in patients with systemic lupus erythematosus and related conditions. J Clin Rheumatol 2001; 7(6): 371-3.
(80) del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44(12): 2737-45.
(81) Dessein PH, Tobias M, Veller MG. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2006; 33(12): 2425-32.
(82) La Montagna G, Cacciapuoti F, Buono R, Manzella D, Mennillo GA, Arciello A, et al. Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diab Vasc Dis Res 2007; 4(2): 130-5.
(83) Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006; 54(9): 2765-75.
(84) Dessein PH, Joffe BI, Stanwix AE, Christian BF, Veller M. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol 2004; 31(5): 867-74.
(85) Paolisso G, Valentini G, Giugliano D, Marrazzo G, Tirri R, Gallo M, et al. Evidence for peripheral impaired glucose handling in patients with connective tissue disease. Metabolism 1991; 40(9): 902-7.
(86) Oeser A, Chung CP, Asanuma Y, Avalos I, Stein CM. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 2005; 52(11): 3651-9.
(87) Inaba M, Tanaka K, Goto H, Sakai S, Yamada S, Naka H, et al. J Rheumatol 2007; 34(2): 290-5.
(88) Bartfai T, Waalen J, Buxbaum JN. Adipose tissue as a modulator of clinical inflammation: does obesity reduce the prevalence of rheumatoid arthritis? J Rheumatol 2007; 34(3): 488-92.
(89) Keyser RE, Rus V, Cade WT, Kalappa N, Flores RH, Handwerger BS. Evidence for aerobic insufficiency in women with systemic Lupus erythematosus. Arthritis Rheum 2003; 49(1): 16-22.
(90) Tench C, Bentley D, Vleck V, McCurdie I, White P, D’ Cruz D. Aerobic fitness, fatigue, and physical disability in systemic lupus erythematosus. J Rheumatol 2002; 29(3): 474-81.
(91) Toloza SM, Uribe AG, McGwin G Jr, Alarcón GS, Fessler BJ, Bastian HM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 50(12): 3947-57.
(92) Ho KT, Ahn CW, Alarcón GS, Baethge BA, Tan FK, Roseman J, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 2005; 44(10): 1303-7.
(93) Ghaussy NO, Sibbitt W Jr, Bankhurst AD, Qualls CR. Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol 2003; 30(6): 1215-21.
(94) Gerli R, Sherer Y, Vaudo G, Schillaci G, Gilburd B, Giordano A, et al. Early atherosclerosis in rheumatoid arthritis: effects of smoking on thickness of the carotid artery intima media. Ann N Y Acad Sci 2005; 1051: 281-90.
(95) Glossop JR, Dawes PT, Mattey DL. Association between cigarette smoking and release of tumour necrosis factor alpha and its soluble receptors by peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006; 45(10): 1223-9.
(96) Papadopoulos NG, Alamanos Y, Voulgari PV, Epagelis EK, Tsifetaki N, Drosos AA. Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheumatol 2005; 23(6): 861-6.
(97) Banerjee KK, Marimuthu P, Sarkar A, Chaudhuri RN. Influence of cigarette smoking on Vitamin C, glutathione and lipid peroxidation status. Indian J Public Health 1998; 42(1): 20-3.
(98) Von Feldt JM, Scalzi LV, Cucchiara AJ, Morthala S, Kealey C, Flagg SD, et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54(7): 2220-7.
(99) López-Olivo MA, González-López L, García-González A, Villa-Manzano AI, Cota-Sánchez AR, Salazar-Paramo M, et al. Factors associated with hyperhomocysteinaemia in Mexican patients with rheumatoid arthritis. Scand J Rheumatol 2006; 35(2): 112-6.
(100) Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352(16): 1685-95.
(101) Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
(102) González-Gay MA, González-Juanatey C, Piñeiro A, García-Porrua C, Testa A, Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005; 32(7): 1219-23.
(103) del Rincón I, Williams K, Stern MP, Freeman GL, O’Leary DH, Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003; 48(7): 1833-40.
(104) Tani C, Mosca M, d’Ascanio A, Versari D, Virdis A, Ghiadoni L, et al. Chronic inflammation and endothelial dysfunction: analysis of a cohort of patients with SLE and UCTD. Reumatismo 2006; 58(3): 212-8.
(105) Ferreira GA, Navarro TP, Telles RW, Carvalho MAP, Sato EI. A terapia immunosuppressive é associada com a melhor função endothelial em pacientes de SLE. Uma comunicação pessoal. São Paulo: Universidade Federal de São Paulo. Escola Paulista de Medicina. Divisão do Reumatologia, 2007.
(106) Popkova TV, Khelkovskaia AN, Mach ES, Aleksandrova EN, Novikov AA, Novikova DS, et al. Cardiovascular diseases in rheumatoid arthritis. Op. cit. ref. 31.
(107) Turesson C, McClelland RL, Christianson TJ, Matteson EL. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2007;
66(1): 70-5.
(108) van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006; 8(5): R151.
(109) MacGregor AJ, Dhillon VB, Binder A, Forte CA, Knight BC, Betteridge DJ, et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 1992; 51(2): 152-5.
(110) del Rincón I, O’Leary DH, Haas RW, Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004; 50(12): 3813-22.
(111) Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107(9): 1303-7
(112) Ahmad Y, Bodill H, Shelmerdine J. Antiphospholipid antibodies (APLA) contribute to atherogenesis in SLE. Op. cit. ref. 18.
(113) Svenungsson E, Jensen-Urstad K, Heimbürger M, Silveira A, Hamsten A, defaire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104(16): 1887-93.
(114) Sherer Y, Gerli R, Gilburd B, Bartoloni Bocci E, Vaudo G, Mannarino E, et al. Thickened carotid artery intima-media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies. Lupus 2007; 16(4): 259-64.
(115) Fischer K, Brzosko M, Walecka A, Ostanek L, Sawicki M. Antiendothelial cell antibodies as a risk factor of atherosclerosis in systemic lupus erythematosus. Ann Acad Med Stetin 2006; 52 (Suppl 2): 95-9.
(116) Asanuma Y, Chung CP, Oeser A, Shintani A, Stanley E, Raggi P, Stein CM. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006; 33(3): 539-45.
(117) Jackson M, Ahmad Y, Bruce IN, Coupes B, Brenchley PE. Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus. Arthritis Res Ther 2006; 8(3): R81.
(118) Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A, Raggi P, et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006; 8(6): R186.
(119) Sella EMC, Sato EI. Avaliaçao de fatores de rsco coronário e dor torácica em lúpus eritematoso sistêmico. Rev bras reumatol 2002; 42(3): 160-8.
(120) Banks M, Pace A, Kitas G. Acute coronary syndromes present atipically and recurr more frequently in rheumatoid arthritis than matched controls. Arthritis Rheum 2001; 44: S53.
(121) Maradit-Kremers H, Crownson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden death in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52(2): 402-11.
(122) Costenbader KH, Wright E, Liang MH, Karlson EW. Cardiac risk factor awareness and management in patients with systemic lupus erythematosus. Arthritis Rheum 2004; 51(6): 983-8.
(123) Haq I, Isenberg D. How does one assess and monitor patients with systemic lupus erythematosus in daily clinical practice? Best Pract Res Clin Rheumatol 2000; 16(2): 181-94.
(124) Nikpour M, Urowitz M, Gladman D. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2005; 31(2): 329-54.
(125) Wallace DJ. What’s New in the management of lupus since 2000? J Clin Rheumatol 2006; 12(6): 307-13.
(126) Rahman A, Bessant R, Isenberg DA. What do lupus specialists believe about managing conventional cardiovascular risk factors in patients with systemic lupus erythematosus? Lupus 2006; 15(10): 697-9.
(127) Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus–proposed guidelines for risk factor management. Rheumatology (Oxford) 2004; 43(1): 7-12.
(128) American Diabetes Association. Standards of medical care in diabetes–2006. Diabetes Care 2006; 29 (Suppl 1): S4-42.
(129) Mancini GB. Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease. Am J Med 1998; 105(1A): 40S-47S.
(130) Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002; 40(3): 505-10.
(131) Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease a meta-analysis of patient-level data. Ann Intern Med 2001; 135(2): 73-87.
(132) Ruggenenti P, Mise N, Pisoni R, Arnoldi F, Pezzotta A, Perna A, et al. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 2003; 107(4): 586-92.
(133) Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19(6): 540-56.
(134) Ferreira GA, Navarro TP, Telles R, Andrade LE, Sato EI. Atorvastatin therapy improves endothelial-dependent vasodilatation in patients with lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 2007; 46(10): 1560-5.
(135) Jury EC, Ehrenstein MR. Statins: immunomodulators for autoimmune rheumatic disease? Lupus 2005; 14(3): 192-6.
(136) Bruce IN. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol 2005; 19(5): 823-38.
(137) Sparrow CP, Burton C, Hernández M, Mundt S, Hassing H, patel S, et al. Simvastatin has antiinflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21(1): 115-21.
(138) Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors:statins as anti-inflammatory agents? Circulation 2004; 109(21 Suppl. 1): II18-26.
(139) Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in NZB/WF1 mice. J Immunol 2004; 173(12): 7641-6.
(140) Jury EC, Ehrenstein MR. Statins: immunomodulators for autoimmune rheumatic disease? Lupus 2005; 14(3): 192-6.
(141) Mäki-Petäjä KM, Booth AD, Hall FC, Wallace SM, Brown J, McEniery CM, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007; 50(9): 852-8.
(142) Van Doornum S, McColl G, Wicks IP. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63(12): 1571-5.
(143) McCarey DW, McInnes LB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebocontrolled trial. Lancet 2004; 363(9426): 2015-21.
(144) Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995; 332(15): 993-7.
(145) Sloop GD. Decreased prevalence of symptomatic atherosclerosis in arthritis patients on long-term aspirin therapy. Angiology 1998; 49(10): 827-32.
(146) Borba EF, Bonfá E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 2001; 28(4): 780-5.
(147) Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000; 27(9): 2142-5.
(148) Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89(3): 322-6.
(149) Sachet JC, Borbá EF, Bonfá E, Vinagre CG, Silva VM, Maranhão RC. Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 2007; 16(4): 273-8.
(150) Johansson E, Forsberg K, Johnsson H. Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasis 1981; 10(2): 89-96.
(151) Prowse C, Pepper D, Dawes J. Prevention of the platelet alphagranule release reaction by membrane-active drugs. Thromb Res 1982; 25(3): 219-27.
(152) Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298(2): 187-93.
(153) Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S. Vascular stiffness with systemic lupus erythematosus. Hypertension 2001; 37(4): 1075-82.
(154) van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Op. cit. ref. 108.
(155) Wållberg-Jonsson S, Ohman M, Rantapää-Dahlqvist S. Which factors are related to the presence of atherosclerosis in rheumatoid arthritis? Scand J Rheumatol 2004; 33(6): 373-9.
(156) Pham T, Gossec L, Constantin A, Pavy S, Bruckert E, Cantagrel A, et al. Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006; 73(4): 379-87.
(157) Choi HK, Seeger JD. Lipid profiles among US elderly with untreated rheumatoid arthritis–the Third National Health and Nutrition Examination Survey. J Rheumatol 2005; 32(12): 2311-6.
(158) Dessein PH, Joffe BI, Stanwix AE. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res 2002; 4(6): R12.
(159) Cardillo C, Schinzari F, Mores N, Mettimano M, Melina D, Zoli A, et al. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis. Clin Pharmacol Ther 2006; 80(3): 275-81.
(160) González-Juanatey C, Llorca J, García-Porrua C, Martin J, González-Gay MA. Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 2006; 55(1): 150-3.
(161) Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006; 33(12): 2440-6.
(162) González-Gay MA, De Matias JM, González-Juanatey C, García-Porrua C, Sánchez-Andrade A, Martin J, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24(1): 83-6.
Descargas
Publicado
2008-06-30
Cómo citar
1.
Silvariño R, Inoue Sato E. Factores de riesgo para aterosclerosis en enfermedades autoinmunitarias sistémicas. Rev. Méd. Urug. [Internet]. 30 de junio de 2008 [citado 21 de noviembre de 2024];24(2):118-32. Disponible en: https://revista.rmu.org.uy/index.php/rmu/article/view/583
Número
Sección
Trabajos de Revisión o Actualización y Puestas al día
